Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to study the activity of vemurafenib in untreated melanoma brain
metastases harboring B-Raf proto-oncogene, serine/threonine kinase (BRAF) mutations that are
not amenable to stereotactic radiosurgery based on size, number of lesions or location, to
measure cerebrospinal fluid (CSF) levels of vemurafenib as an indicator of central nervous
system penetrance and to measure levels of vemurafenib in normal brain tissue and brain
metastases in those in whom surgical management is feasible.